Personal information

No personal information available

Activities

Collapse all

Employment (2)

Canberra Hospital: Canberra, Australian Capital Territory, AU

2019-02-01 to present (Medical Oncology)
Employment
Source: Self-asserted source
Yada Kanjanapan

Princess Margaret Cancer Centre: Toronto, ON, CA

2016-04-01 to 2018-04-01
Employment
Source: Self-asserted source
Yada Kanjanapan

Education and qualifications (1)

University of Adelaide: Adelaide, AU

2008-12-18 | MBBS
Education
Source: Self-asserted source
Yada Kanjanapan

Works (18)

Characteristics and risk factors for microbial infections during cancer immune checkpoint therapy.

Cancer medicine
2020-11 | Journal article
DOI: 10.1002/cam4.3532
PMID: 33159505
PMC: PMC7724496
Contributors: Kanjanapan Y; Yip D
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Considerations for cancer immunotherapy during the COVID-19 pandemic.

The Medical journal of Australia
2020-10 | Journal article
DOI: 10.5694/mja2.50805
PMID: 33034044
PMC: PMC7675256
Contributors: Kanjanapan Y; Yip D
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.

Breast cancer research and treatment
2020-08 | Journal article
DOI: 10.1007/s10549-020-05825-w
PMID: 32779037
Contributors: Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Response to multidisciplinary therapy of metastatic anaplastic thyroid cancer involving the right internal jugular vein and superior vena cava.

ANZ journal of surgery
2020-08 | Journal article
DOI: 10.1111/ans.16208
PMID: 32761871
Contributors: Mai JYL; Ebrahimi A; Lee A; Kanjanapan Y; Perampalam S; Connors J; Chou W; Liang X
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Acute ischaemic stroke following cisplatin-based chemotherapy for testicular cancer.

BMJ case reports
2020-05 | Journal article
DOI: 10.1136/bcr-2020-235005
PMID: 32439748
Contributors: Kanjanapan Y; Gilbourd D; Pranavan G
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index.

JNCI cancer spectrum
2019-09 | Journal article
DOI: 10.1093/jncics/pkz071
PMID: 32337489
PMC: PMC7050022
Contributors: Day D; Guo C; Kanjanapan Y; Tran B; Spreafico A; Joshua AM; Wang L; Abdul Razak AR; Leighl NB; Hansen AR et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Novel patterns of response under immunotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology
2019-03 | Journal article
DOI: 10.1093/annonc/mdz003
PMID: 30657859
Contributors: Borcoman E; Kanjanapan Y; Champiat S; Kato S; Servois V; Kurzrock R; Goel S; Bedard P; Le Tourneau C
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.

Cancer
2019-02 | Journal article
DOI: 10.1002/cncr.31999
PMID: 30768786
Contributors: Kanjanapan Y; Day D; Wang L; Al-Sawaihey H; Abbas E; Namini A; Siu LL; Hansen A; Razak AA; Spreafico A et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Journal of the National Cancer Institute
2019-02 | Journal article
DOI: 10.1093/jnci/djy196
PMID: 30561713
PMC: PMC6376915
Contributors: Hobbs BP; Barata PC; Kanjanapan Y; Paller CJ; Perlmutter J; Pond GR; Prowell TM; Rubin EH; Seymour LK; Wages NA et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

European journal of cancer (Oxford, England : 1990)
2018-12 | Journal article
DOI: 10.1016/j.ejca.2018.10.017
PMID: 30529898
Contributors: Kanjanapan Y; Day D; Butler MO; Wang L; Joshua AM; Hogg D; Leighl NB; Razak ARA; Hansen AR; Boujos S et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Niraparib for the treatment of ovarian cancer.

Expert opinion on pharmacotherapy
2017-04 | Journal article
DOI: 10.1080/14656566.2017.1297423
PMID: 28299955
Contributors: Kanjanapan Y; Lheureux S; Oza AM
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Glut-1 expression in small cervical biopsies is prognostic in cervical cancers treated with chemoradiation.

Clinical and translational radiation oncology
2017-02 | Journal article
DOI: 10.1016/j.ctro.2017.01.003
PMID: 29658001
PMC: PMC5893520
Contributors: Kanjanapan Y; Deb S; Young RJ; Bressel M; Mileshkin L; Rischin D; Hofman MS; Narayan K; Siva S
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.

Internal medicine journal
2016-11 | Journal article
DOI: 10.1111/imj.13202
PMID: 27507629
Contributors: Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Prognostic significance of KIT exon 11 deletion mutation in intermediate-risk gastrointestinal stromal tumor.

Asia-Pacific journal of clinical oncology
2016-10 | Journal article
DOI: 10.1111/ajco.12603
PMID: 27753268
Contributors: Quek R; Farid M; Kanjanapan Y; Lim C; Tan IB; Kesavan S; Lim TKH; Oon LL; Goh BK; Chan WH et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Patterns of care for metastatic renal cell carcinoma in Australia.

BJU international
2015-07 | Journal article
DOI: 10.1111/bju.13176
PMID: 26204961
Contributors: Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Andrews M; Davis ID; Azad AA; Rosenthal M; Wong S et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib.

European journal of cancer (Oxford, England : 1990)
2015-03 | Journal article
DOI: 10.1016/j.ejca.2015.02.015
PMID: 25801699
Contributors: Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; Mcarthur G et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure.

Internal medicine journal
2013-11 | Journal article
DOI: 10.1111/imj.12283
PMID: 24237647
Contributors: Farinola N; Kanjanapan Y
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Folic acid prevents and partially reverses glucocorticoid-induced hypertension in the rat.

American journal of hypertension
2007-03 | Journal article
DOI: 10.1016/j.amjhyper.2006.08.007
PMID: 17324744
Contributors: Miao Y; Zhang Y; Lim PS; Kanjanapan Y; Mori TA; Croft KD; Earl J; Lee SY; McKenzie KU; Hu L et al.
Source: Self-asserted source
Yada Kanjanapan via Europe PubMed Central

Peer review (4 reviews for 3 publications/grants)

Review activity for Advances in therapy. (1)
Review activity for Breast cancer research and treatment. (1)
Review activity for Oncology and therapy. (2)
How many people are using ORCID?